SCHEMBL2934668

SCHEMBL2934668

CC(NCc1ccc(OCc2cccc(F)c2)c(Cc2cccc(F)c2)c1)C(N)=O

nearest known ligand 0.70

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MAOB P27338 7/20 0.70
MAOA P21397 4/20 0.70
SCN9A Q15858 2/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30569967 1.00 MAOB (0.70) MAOBMAOASCN9A
SCHEMBL30569984 1.00 MAOB (0.70) MAOBMAOASCN9A
SCHEMBL2934667 1.00 MAOB (0.70) MAOBMAOASCN9A
SCHEMBL2935454 1.00 MAOB (0.70) MAOBMAOASCN9A
SCHEMBL2936910 0.96 MAOB (0.66) MAOBMAOASCN9A
SCHEMBL2939110 0.96 MAOB (0.66) MAOBMAOASCN9A
SCHEMBL2938202 0.96 MAOB (0.66) MAOBMAOASCN9A
SCHEMBL22958444 0.95 MAOB (0.64) MAOBMAOASCN9A
SCHEMBL4161201 0.93 MAOB (0.72) MAOBMAOASCN9A
SCHEMBL4161204 0.93 MAOB (0.72) MAOBMAOASCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210040033-A1 PROCESS FOR PREPARING SAFINAMIDE MEDICHEM, S.A. (ES) 2021-02-11 US claimed
EP-3772510-A1 PROCESS FOR PREPARING SAFINAMIDE Medichem, S.A. (ES) 2021-02-10 EP claimed
EP-3257842-B1 THERAPEUTIC USE OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE NEWRON PHARM SPA (IT) 2020-11-18 EP claimed
EP-3257842-A1 PROCESS FOR THE PRODUCTION OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE Newron Pharmaceuticals S.p.A. (IT) 2017-12-20 EP claimed
EP-2229351-B1 PROCESS FOR THE PRODUCTION OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE NEWRON PHARM SPA (IT) 2017-11-08 EP claimed
EP-2474521-B1 High purity degree 2-[4-(3- and 2-fluorobenzyloxy)benzylamino]propanamides for use as medicaments and pharmaceutical formulations containing them NEWRON PHARM SPA (IT) 2016-08-10 EP claimed
EP-2029524-B1 PROCESS FOR THE PRODUCTION OF 2- [4 - ( 3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPAN AMIDES NEWRON PHARM SPA (IT) 2014-11-26 EP claimed
US-8846763-B2 High purity 2-[4-(3- or 2-fluorobenzyloxy)benzylamino] propanamides and methods of use thereof NEWRON PHARMACEUTICALS, S.P.A. (IT) 2014-09-30 US claimed
US-20140051758-A1 HIGH PURITY 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO] PROPANAMIDES AND METHODS OF USE THEREOF NEWRON PHARMACEUTICALS S.P.A. (IT) 2014-02-20 US claimed
CN-103284984-A Process for the production of 2-[4-(3- and 2-flu0r0benzyl0xy)benzylamin0]propanamides NEWRON PHARM SPA 2013-09-11 CN claimed
US-8278485-B2 Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides NEWRON PHARMACEUTICALS S.P.A. (IT) 2012-10-02 US claimed
EP-2474521-A1 High purity degree 2-[4-(3- and 2-fluorobenzyloxy)benzylamino]propanamides for use as medicaments and pharmaceutical formulations containing them Newron Pharmaceuticals S.p.A. (IT) 2012-07-11 EP claimed
US-20120157712-A1 PROCESS FOR THE PRODUCTION OF 2-[4-(3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPANAMIDES NEWRON PHARMACEUTICALS S.P.A. (IT) 2012-06-21 US claimed
US-8076515-B2 Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides NEWRON PHARMACEUTICALS S.P.A. (IT) 2011-12-13 US claimed
US-20100324141-A1 HIGH PURITY 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES AND METHODS OF USE THEREOF NEWRON PHARMACEUTICALS S.P.A. (IT) 2010-12-23 US claimed
EP-2229351-A1 PROCESS FOR THE PRODUCTION OF 2-Ý4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO¨PROPANAMIDES WITH HIGH PURITY DEGREE Newron Pharmaceuticals S.p.A. (IT) 2010-09-22 EP claimed
WO-2009074478-A1 PROCESS FOR THE PRODUCTION OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE NEWRON PHARMACEUTICALS S.P.A. (IT) 2009-06-18 WO claimed
US-20090156678-A1 PROCESS FOR THE PRODUCTION OF 2-[4-(3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPANAMIDES NEWRON PHARMACEUTICALS S.P.A. (IT) 2009-06-18 US claimed
EP-2029524-A1 PROCESS FOR THE PRODUCTION OF 2- [4 - ( 3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPAN AMIDES Newron Pharmaceuticals S.p.A. (IT) 2009-03-04 EP claimed
WO-2007147491-A1 PROCESS FOR THE PRODUCTION OF 2- [4 - ( 3- AND 2-FLU0R0BENZYL0XY) BENZYLAMIN0] PROPAN AMIDES NEWRON PHARMACEUTICALS S.P.A. (IT) 2007-12-27 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156678-A1 PROCESS FOR THE PRODUCTION OF 2-[4-(3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPANAMIDES PTMA, PSMB2, PDGFRA MAOB 129/4885MAOA 200/4885SCN9A 407/4885
US-20140051758-A1 HIGH PURITY 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO] PROPANAMIDES AND METHODS OF USE THEREOF KCNH3, KCNB2, KCNH2 MAOB 149/4885MAOA 473/4885SCN9A 146/4885
US-20100324141-A1 HIGH PURITY 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES AND METHODS OF USE THEREOF PDE7A, PDE8B, PDE9A MAOB 53/4885MAOA 179/4885SCN9A 147/4885
US-20210040033-A1 PROCESS FOR PREPARING SAFINAMIDE SRM, COASY, DHPS MAOB 1147/4885MAOA 1654/4885SCN9A 167/4885
US-20120157712-A1 PROCESS FOR THE PRODUCTION OF 2-[4-(3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPANAMIDES PTMA, PSMB2, PDGFRA MAOB 129/4885MAOA 200/4885SCN9A 407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.